-
公开(公告)号：US20150191466A1
公开(公告)日：2015-07-09
申请号：US14628876
申请日：2015-02-23
Applicant: Genzyme Corporation
Inventor： John L. KANE, JR. , Gloria MATTHEWS , Markus METZ , Michael KOTHE , Jinyu LIU , Andrew SCHOLTE
IPC: C07D471/04 , C07D401/14 , C07D471/08 , C07D403/04 , C07D519/00 , C07D471/10 , C07D405/14 , C07D401/12 , C07D413/14
CPC classification number: A61K31/551 , A61K31/4184 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/4725 , A61K31/496 , A61K31/501 , A61K31/506 , A61K31/5377 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D413/04 , C07D413/14 , C07D417/14 , C07D471/04 , C07D471/08 , C07D471/10 , C07D487/04 , C07D487/08 , C07D487/10 , C07D519/00 , C07F9/5022 , C07F9/6506 , C07F9/65583 , C07F9/6561
Abstract: Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-related kinase B (TrkB), tropomyosin-related kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)).
Abstract translation: 原肌球蛋白相关激酶抑制剂（Trk抑制剂）是用于治疗疾病的小分子化合物。 Trk抑制剂可用作药剂和药物组合物。 Trk抑制剂可用于治疗炎性疾病，自身免疫性疾病，骨代谢缺陷和/或癌症，并且特别可用于治疗骨关节炎（OA），疼痛和与OA相关的疼痛。 Trk抑制剂也可用于抑制原肌球蛋白相关激酶A（TrkA），原肌球蛋白相关激酶B（TrkB），原肌球蛋白相关激酶C（TrkC）和/或c-FMS（集落刺激因子-1的细胞受体 （CSF-1））。
-
公开(公告)号：US20250026749A1
公开(公告)日：2025-01-23
申请号：US18777773
申请日：2024-07-19
Applicant: Genzyme Corporation
Inventor： Elyse BOURQUE , Mario A. CABRERA-SALAZAR , Cassandra CELATKA , Seng H. CHENG , Bradford HIRTH , Andrew GOOD , Katherine JANCSICS , John MARSHALL , Markus METZ , Ronald K. SCHEULE , Renato SKERLJ , Yibin XIANG , Zhong ZHAO , John LEONARD , Thomas NATOLI , Elina MAKINO , Herve HUSSON , Oxana BESKROVNAYA
IPC: C07D453/02 , A61K31/439 , A61K31/496 , A61K31/497 , A61K31/506 , A61K31/5377 , A61K31/55 , A61K31/551 , A61K45/06 , C07D471/08
Abstract: The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment of metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, cystic disease and for the treatment of cancer.
-
公开(公告)号：US20140255381A1
公开(公告)日：2014-09-11
申请号：US14030725
申请日：2013-09-18
Applicant: GENZYME CORPORATION
Inventor： Elyse BOURQUE , Cassandra CELATKA , Bradford HIRTH , Markus METZ , Zhong ZHAO , Renato SKLERJ , Yibin XIANG , Katherine JANCSICS , John MARSHALL , Seng CHENG , Ronald SCHEULE , Mario CABRERA-SALAZAR , Andrew GOOD
IPC: C07D453/02 , A61K38/47 , A61K31/439
CPC classification number: C07D487/08 , A61K31/439 , A61K31/454 , A61K31/46 , A61K31/506 , A61K31/551 , A61K38/47 , C07D453/00 , C07D453/02 , C07D455/02 , C12Y302/01022
Abstract: The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer.
Abstract translation: 本发明涉及可用于单独或与酶替代疗法组合治疗代谢性疾病如溶酶体贮积病的葡萄糖神经酰胺合成酶（GCS）抑制剂和癌症治疗。
-
公开(公告)号：US20210261557A1
公开(公告)日：2021-08-26
申请号：US17242016
申请日：2021-04-27
Applicant: GENZYME CORPORATION
Inventor： Elyse BOURQUE , Mario CABRERA-SALAZAR , Cassandra CELATKA , Seng CHENG , Mary A. CROMWELL , Andrew GOOD , Bradford HIRTH , Katherine JANCSICS , John P. LEONARD , Lingyun LI , James LILLIE , Hanlan LIU , Elina MAKINO , John MARSHALL , Paul MASON , Markus METZ , Fazeela MORSHED , Thomas O'SHEA , Ronald SCHEULE , Renato SKERLJ , Bing WANG , Yibin XIANG , Zhong ZHAO
IPC: C07D487/08 , A61K31/439 , A61K31/454 , A61K38/47 , C07D453/02 , C07D453/00 , A61K31/46 , A61K31/506 , A61K31/551 , C07D455/02
Abstract: The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment of metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer.
-
公开(公告)号：US20150274725A1
公开(公告)日：2015-10-01
申请号：US14741017
申请日：2015-06-16
Applicant: Genzyme Corporation
Inventor： John L. KANE, JR. , Gloria MATTHEWS , Markus METZ , Michael KOTHE , Jinyu LIU , Andrew SCHOLTE
IPC: C07D471/04 , C07D403/04 , C07D471/10 , C07D401/14 , C07D413/14 , C07D405/14 , C07F9/50 , C07D401/04
CPC classification number: A61K31/551 , A61K31/4184 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/4725 , A61K31/496 , A61K31/501 , A61K31/506 , A61K31/5377 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D413/04 , C07D413/14 , C07D417/14 , C07D471/04 , C07D471/08 , C07D471/10 , C07D487/04 , C07D487/08 , C07D487/10 , C07D519/00 , C07F9/5022 , C07F9/6506 , C07F9/65583 , C07F9/6561
Abstract: Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-related kinase B (TrkB), tropomyosin-related kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)).
-
Patent Agency Ranking
公开(公告)号：US20140371460A1
公开(公告)日：2014-12-18
申请号：US14471958
申请日：2014-08-28
Applicant: Genzyme Corporation
Inventor： Elyse BOURQUE , Cassandra CELATKA , Bradford HIRTH , Markus METZ , Zhong ZHAO , Renato SKLERJ , Yibin XIANG , Katherine JANCSICS , John MARSHALL , Seng CHENG , Ronald SCHEULE , Mario CABRERA-SALAZAR , Andrew GOOD
IPC: C07D453/02
CPC classification number: C07D487/08 , A61K31/439 , A61K31/454 , A61K31/46 , A61K31/506 , A61K31/551 , A61K38/47 , C07D453/00 , C07D453/02 , C07D455/02 , C12Y302/01022
Abstract: The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer.
-
公开(公告)号：US20220073508A1
公开(公告)日：2022-03-10
申请号：US17230385
申请日：2021-04-14
Applicant: Genzyme Corporation
Inventor： Elyse BOURQUE , Mario A. CABRERA-SALAZAR , Cassandra CELATKA , Seng H. CHENG , Bradford HIRTH , Andrew GOOD , Katherine JANCSICS , John MARSHALL , Markus METZ , Ronald K. SCHEULE , Renato SKERLJ , Yibin XIANG , Zhong ZHAO , John LEONARD , Thomas NATOLI , Elina MAKINO , Herve HUSSON , Oxana BESKROVNAYA
IPC: C07D453/02 , C07D471/08 , A61K31/439 , A61K31/496 , A61K31/497 , A61K31/506 , A61K31/5377 , A61K31/55 , A61K31/551 , A61K45/06
Abstract: The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment of metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, cystic disease and for the treatment of cancer.
-
公开(公告)号：US20200048266A1
公开(公告)日：2020-02-13
申请号：US16542166
申请日：2019-08-15
Applicant: GENZYME CORPORATION
Inventor： Elyse BOURQUE , Mario CABRERA-SALAZAR , Cassandra CELATKA , Seng CHENG , Mary A. CROMWELL , Andrew GOOD , Bradford HIRTH , Katherine JANCSICS , John P. LEONARD , Lingyun LI , James LILLIE , Hanlan LIU , Elina MAKINO , John MARSHALL , Paul MASON , Markus METZ , Fazeela MORSHED , Thomas O'SHEA , Ronald SCHEULE , Renato SKERLJ , Bing WANG , Yibin XIANG , Zhong ZHAO
IPC: C07D487/08 , A61K31/439 , A61K31/454 , A61K38/47 , C07D453/02 , C07D453/00 , A61K31/46 , A61K31/506 , A61K31/551 , C07D455/02
Abstract: The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment of metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer.
-
公开(公告)号：US20190183903A1
公开(公告)日：2019-06-20
申请号：US16194696
申请日：2018-11-19
Applicant: Genzyme Corporation
Inventor： John L. KANE, JR. , Gloria MATTHEWS , Markus METZ , Michael KOTHE , Jinyu LIU , Andrew SCHOLTE
IPC: A61K31/551 , C07F9/6506 , C07D471/08 , C07D403/14 , C07D401/12 , C07D487/04 , C07D405/14 , C07D401/14 , C07D401/04 , C07D403/04 , A61K31/4725 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/496 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K31/4184 , C07F9/6561 , C07F9/6558 , C07D471/04 , C07D487/08 , C07D417/14 , C07D413/14 , C07F9/50 , C07D519/00 , C07D471/10 , C07D413/04 , C07D487/10
CPC classification number: A61K31/551 , A61K31/4184 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/4725 , A61K31/496 , A61K31/501 , A61K31/506 , A61K31/5377 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D413/04 , C07D413/14 , C07D417/14 , C07D471/04 , C07D471/08 , C07D471/10 , C07D487/04 , C07D487/08 , C07D487/10 , C07D519/00 , C07F9/5022 , C07F9/6506 , C07F9/65583 , C07F9/6561
Abstract: Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-related kinase B (TrkB), tropomyosin-related kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)).
-
公开(公告)号：US20160207933A1
公开(公告)日：2016-07-21
申请号：US14835402
申请日：2015-08-25
Applicant: GENZYME CORPORATION
Inventor： Elyse BOURQUE , Mario CABRERA-SALAZAR , Cassandra CELATKA , Seng CHENG , Mary A. CROMWELL , Andrew GOOD , Bradford HIRTH , Katherine JANCSICS , John P. LEONARD , Lingyun LI , James LILLIE , Hanlan LIU , Elina MAKINO , John MARSHALL , Paul MASON , Markus METZ , Fazeela MORSHED , Thomas O'SHEA , Ronald SCHEULE , Renato SKERLJ , Bing WANG , Yibin XIANG , Zhong ZHAO
IPC: C07D487/08 , A61K31/439 , A61K38/47 , A61K31/551 , C07D455/02 , A61K31/46 , C07D453/02 , A61K31/506
Abstract: The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer.
Abstract translation: 本发明涉及可用于单独或与酶替代疗法组合治疗代谢性疾病如溶酶体贮积病的葡萄糖神经酰胺合成酶（GCS）抑制剂和癌症治疗。
-
-
-
-
-
-
-
-
-
Search Results
13
records
(took 0.022 seconds)
